Innovation is targeted to stop bioterror now
Genia Long 13, is an expert in the economics and business strategy of innovation and growth. She has assisted executives in pharmaceuticals and biotechnology related fields. Works for Analysis Group. 2013. “Innovation in the Biopharmaceutical Pipeline: A Multidimensional View” http://phrmadocs.phrma.org/sites/default/files/pdf/2013innovationinthebiopharmaceuticalpipeline-analysisgroupfinal.pdf
There are also a range of medicines in development in areas relevant to the needs of national security, the United States military, and victims of natural disasters. For example, research is under way to address various potential bioterrorism agents, which may cause death or disease in humans, animals, or plants.
While the most recently FDA-approved treatment for anthrax, a highly dangerous, potential bioterrorism
agent, was in 1987, there are now a dozen potential NMEs in development, one of which was just
approved by the FDA.